|
Click on link to view section or document |
|
1. Entire Document including Exhibit(s)
|
| 2. S-1/A
|
| PAGE: 1 - The registrant hereby amends this registration statement on such date or dates as may be necessary t |
| PAGE: 2 - The information contained in this prospectus is not complete and may be changed. We may not sell the |
| PAGE: 3 - Neither the Securities and Exchange Commission nor any state securities commission has approved or d |
| PAGE: 4 - TABLE OF CONTENTS |
| PAGE: 5 - PROSPECTUS SUMMARY |
| PAGE: 6 - Duromist |
| PAGE: 7 - Going Concern and Management s Plan |
| PAGE: 8 - SUMMARY OF THE OFFERING |
| PAGE: 9 - SUMMARY OF SELECTED FINANCIAL INFORMATION |
| PAGE: 10 - RISK FACTORS |
| PAGE: 11 - |
| PAGE: 12 - We will require significant capital for product development and commercialization in the near term. |
| PAGE: 13 - Our additional financing requirements could result in dilution to existing stockholders. |
| PAGE: 14 - Our business and revenue is dependent on the successful development of our products. |
| PAGE: 15 - We do not have commercially available products. |
| PAGE: 16 - Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sa |
| PAGE: 17 - We face intense competition. |
| PAGE: 18 - Extensive government regulation may affect our business. |
| PAGE: 19 - We expect to face uncertainty over reimbursement and healthcare reform. |
| PAGE: 20 - If we cannot protect our intellectual property, other companies could use our technology in competit |
| PAGE: 21 - Even if we obtain patents to protect our products, those patents may not be sufficiently broad and o |
| PAGE: 22 - Intellectual property rights of third parties could limit our ability to market our products. |
| PAGE: 23 - We are dependent on existing management and board members. |
| PAGE: 24 - Because the average daily trading volume of our common stock is low, the ability to sell our shares |
| PAGE: 25 - Penny stock regulations may impose certain restrictions on marketability of our securities. |
| PAGE: 26 - Shares eligible for future sale may adversely affect the market. |
| PAGE: 27 - Provisions of our certificate of incorporation and Delaware law could deter a change of our manageme |
| PAGE: 28 - The uncertainty created by current economic conditions and possible terrorist attacks and military r |
| PAGE: 29 - You will experience immediate and substantial dilution as a result of this offering. |
| PAGE: 30 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS |
| PAGE: 31 - USE OF PROCEEDS |
| PAGE: 32 - CAPITALIZATION |
| PAGE: 33 - DILUTION |
| PAGE: 34 - DESCRIPTION OF BUSINESS |
| PAGE: 35 - |
| PAGE: 36 - |
| PAGE: 37 - |
| PAGE: 38 - Agreement with BioAlliance Pharma SA |
| PAGE: 39 - Manufacturing |
| PAGE: 40 - Competition |
| PAGE: 41 - Buccal Nonpolar Sprays |
| PAGE: 42 - Buccal Polar Sprays |
| PAGE: 43 - Buccal Polar/Nonpolar Sprays or Capsules |
| PAGE: 44 - Stable Hydroalcoholic Oral Spray Formulations and Methods |
| PAGE: 45 - Stable Anti-Nausea Oral Spray Formulations and Methods. |
| PAGE: 46 - |
| PAGE: 47 - The Hatch-Waxman Act |
| PAGE: 48 - Section 505(b)(2) New Drug Applications |
| PAGE: 49 - Anti-Kickback, False Claims Laws The Prescription Drug Marketing Act |
| PAGE: 50 - MANAGEMENT |
| PAGE: 51 - Steven B. Ratoff |
| PAGE: 52 - DESCRIPTION OF PROPERTY |
| PAGE: 53 - PRICE RANGE OF COMMON STOCK |
| PAGE: 54 - SELECTED FINANCIAL INFORMATION |
| PAGE: 55 - |
| PAGE: 56 - SUPPLEMENTARY FINANCIAL INFORMATION |
| PAGE: 57 - MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND |
| PAGE: 58 - Duromist |
| PAGE: 59 - Other Product Candidates |
| PAGE: 60 - Years Ended December 31, 2009 and December 31, 2008 |
| PAGE: 61 - |
| PAGE: 62 - Years Ended December 31, 2008 and December 31, 2007 |
| PAGE: 63 - Liquidity and Capital Resources |
| PAGE: 64 - Contractual Obligations |
| PAGE: 65 - |
| PAGE: 66 - Recent Accounting Pronouncement |
| PAGE: 67 - DIRECTORS AND NAMED EXECUTIVE OFFICERS |
| PAGE: 68 - Charles Nemeroff, M.D., Ph.D. |
| PAGE: 69 - Thomas E. Bonney, CPA |
| PAGE: 70 - Michael E. Spicer |
| PAGE: 71 - Compensation Objectives and Philosophy |
| PAGE: 72 - Role of Compensation Consultant |
| PAGE: 73 - Components of Compensation |
| PAGE: 74 - Changes for Fiscal Year 2010 |
| PAGE: 75 - Change for Fiscal Year 2010 |
| PAGE: 76 - Long-Term Incentive Equity Awards |
| PAGE: 77 - Stock Options. |
| PAGE: 78 - Executive Benefits and Perquisites |
| PAGE: 79 - Summary Compensation Table |
| PAGE: 80 - |
| PAGE: 81 - All Other Compensation 2009 |
| PAGE: 82 - Outstanding Equity Awards at Fiscal Year-End |
| PAGE: 83 - Option Exercises and Stock Vested During 2009 |
| PAGE: 84 - Potential Payments Upon Termination or Change in Control |
| PAGE: 85 - David H. Bergstrom, Ph.D |
| PAGE: 86 - |
| PAGE: 87 - Deni M. Zodda |
| PAGE: 88 - Steven B. Ratoff. |
| PAGE: 89 - DIRECTOR COMPENSATION |
| PAGE: 90 - Fiscal 2009 Policy |
| PAGE: 91 - Compensation Committee Interlocks and Insider Participation |
| PAGE: 92 - SECURITY OWNERSHIP OF DIRECTORS, MANAGEMENT AND CERTAIN BENEFICIAL OWNERS |
| PAGE: 93 - Stock Ownership of Certain Beneficial Owners |
| PAGE: 94 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS |
| PAGE: 95 - PLAN OF DISTRIBUTION |
| PAGE: 96 - European Economic Area |
| PAGE: 97 - DESCRIPTION OF SECURITIES |
| PAGE: 98 - LEGAL MATTERS |
| PAGE: 99 - NovaDel Pharma Inc. |
| PAGE: 100 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM |
| PAGE: 101 - NOVADEL PHARMA INC. |
| PAGE: 102 - NOVADEL PHARMA INC. |
| PAGE: 103 - NOVADEL PHARMA INC. |
| PAGE: 104 - NOVADEL PHARMA INC. |
| PAGE: 105 - NOVADEL PHARMA INC. |
| PAGE: 106 - NOTE 2 - LIQUIDITY AND BASIS OF PRESENTATION |
| PAGE: 107 - NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
| PAGE: 108 - |
| PAGE: 109 - NOTE 4 CONVERTIBLE NOTES |
| PAGE: 110 - |
| PAGE: 111 - |
| PAGE: 112 - Debt with Conversion and Other Options. |
| PAGE: 113 - Compensation-Stock Compensation. |
| PAGE: 114 - NOTE 7 - RELATED PARTY TRANSACTIONS |
| PAGE: 115 - NOTE 9 - COMMITMENTS AND CONTINGENCIES |
| PAGE: 116 - |
| PAGE: 117 - NOTE 10 OTHER, NET |
| PAGE: 118 - NOTE 11 ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES |
| PAGE: 119 - |
| PAGE: 120 - NOTE 13 - STOCK OPTIONS AND WARRANTS |
| PAGE: 121 - |
| PAGE: 122 - |
| PAGE: 123 - NOTE 14 SUBSEQUENT EVENTS |
| PAGE: 124 - NOTE 15 QUARTERLY RESULTS OF OPERATIONS (UNAUDITED) |
| PAGE: 125 - |
| PAGE: 126 - NovaDel Pharma Inc. |
| PAGE: 127 - NOVADEL PHARMA INC. |
| PAGE: 128 - NOVADEL PHARMA INC. |
| PAGE: 129 - NOVADEL PHARMA INC. |
| PAGE: 130 - NOVADEL PHARMA INC. |
| PAGE: 131 - NOVADEL PHARMA INC. |
| PAGE: 132 - NOTE 5 Derivative Liability |
| PAGE: 133 - NOTE 6 Stock Based Compensation |
| PAGE: 134 - NOTE 9 Deferred Revenue from Licensing Agreements |
| PAGE: 135 - 45,454,545 UNITS |
| PAGE: 136 - PART II |
| PAGE: 137 - |
| PAGE: 138 - ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES |
| PAGE: 139 - |
| PAGE: 140 - |
| PAGE: 141 - |
| PAGE: 142 - ITEM 17. UNDERTAKINGS. |
| PAGE: 143 - |
| PAGE: 144 - SIGNATURES |
| PAGE: 145 - SIGNATURES |
| 3. EX-5.1 - Opinion regarding legality
|
| PAGE: 1 - Exhibit 5.1 |
F 888.329.6696